Emerald Advisers LLC Sells 76,472 Shares of KalVista Pharmaceuticals, Inc. $KALV

Emerald Advisers LLC lessened its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 5.7% during the first quarter, HoldingsChannel reports. The firm owned 1,264,023 shares of the specialty pharmaceutical company’s stock after selling 76,472 shares during the quarter. Emerald Advisers LLC’s holdings in KalVista Pharmaceuticals were worth $25,445,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of KALV. BNP Paribas Financial Markets lifted its position in shares of KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in KalVista Pharmaceuticals in the third quarter valued at about $55,000. Truvestments Capital LLC grew its position in KalVista Pharmaceuticals by 253.8% in the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after acquiring an additional 3,360 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in KalVista Pharmaceuticals by 816.8% during the second quarter. Tower Research Capital LLC TRC now owns 8,059 shares of the specialty pharmaceutical company’s stock worth $91,000 after acquiring an additional 7,180 shares in the last quarter. Finally, Sei Investments Co. acquired a new position in KalVista Pharmaceuticals during the third quarter worth about $145,000.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 21st. Stifel Nicolaus upped their price target on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Needham & Company LLC cut KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 30th. JonesTrading downgraded KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 30th. Finally, Leerink Partners downgraded KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Three research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $33.25.

Insiders Place Their Bets

In related news, CEO Benjamin L. Palleiko sold 10,926 shares of the company’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $26.78, for a total transaction of $292,598.28. Following the sale, the chief executive officer owned 479,989 shares in the company, valued at $12,854,105.42. This represents a 2.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Paul K. Audhya sold 2,239 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $26.78, for a total value of $59,960.42. Following the sale, the insider directly owned 150,260 shares of the company’s stock, valued at $4,023,962.80. This represents a 1.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 39,971 shares of company stock worth $965,493 in the last quarter. 4.30% of the stock is currently owned by company insiders.

KalVista Pharmaceuticals Stock Performance

NASDAQ KALV opened at $27.00 on Tuesday. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of -7.80 and a beta of -0.12. KalVista Pharmaceuticals, Inc. has a twelve month low of $9.83 and a twelve month high of $27.00. The stock has a fifty day simple moving average of $26.90 and a 200 day simple moving average of $20.54. The company has a quick ratio of 5.10, a current ratio of 5.17 and a debt-to-equity ratio of 8.18.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The company had revenue of $40.86 million during the quarter, compared to analyst estimates of $39.03 million. Sell-side analysts expect that KalVista Pharmaceuticals, Inc. will post -1.19 EPS for the current year.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.